Multivalent sdAb Development
Creative Biolabs has been a long-term expert in the field of single domain antibody (sdAb) discovery and development. With years of experience and novel MUsdAb™ platform, our scientists can develop multivalent sdAb with a variety of formats to meet your specific project demands.
Introduction
sdAb, generated from the VHH domain of heavy-chain antibody identified in camelids (e.g. dromedaries, camels, llamas, and alpacas) or the VNAR domain of cartilaginous fishes (e.g. shark) heavy-chain antibody, is the smallest antibody fragment which takes a great deal of advantages to be a potential candidate for either therapeutic or diagnostic applications. Owing to its unique properties of small size, high permeability, and extreme stability, sdAb is also an excellent module that can tolerate various engineering development. Currently, multivalent sdAbs (e.g. bispecific sdAb) have presented a promising prospect to be a more effective solution than the conventional scFv/Fab/IgG-based bispecific antibodies.
Generation of Multivalent sdAb
The development of multivalent sdAb presents great impacts on medicine. As an ideal module to generate bispecific as well as multi-specific antibody molecules, the development of multivalent sdAb provides various alternative antibody formats with modified architectures. Creative Biolabs has built the novel MUsdAb™ platform for the generation of multivalent sdAbs. Through fusing a sdAb with other antibody fragments, Fc fragment, or other specific constructs, a series of multivalent sdAbs can be designed properly without compromising its original target binding affinity. Our scientists will work closely to understand your core requirements to give the most suitable solution to achieve your purpose.
Fig.1 VHH module with various engineering formats. (Iezzi, et al., 2018)
Multivalent sdAb in Clinical Trial
Currently, there are several multivalent sdAbs with different tandem formations in clinical trials. For instance, there is a bivalent monospecific sdAb targeting von Willebrand factor (vWF) with no half-life extension; a trivalent bispecific sdAb targeting vWF with HSA binding ability and half-life extension; a bivalent bispecific sdAb targeting IL6R with HSA binding ability; a trivalent trispecific sdAb targeting IL-17F and IL-17A/F with HSA binding ability; HER2-S-Fab presents a potent tumor growth inhibition in the human tumor xenografts model. In brief, the multivalent sdAb has become more and more important in drug discovery. With our extensive experience in sdAb development, Creative Biolabs can help you achieve even the most challenging design and validation for a unique multivalent sdAb.
Fig.2 Multivalent sdAbs with different tandem formations.
Features of Multivalent sdAb
- Small size and great penetrability
- Outgoing affinity and specificity
- High stability and low immunogenic potential
- Favorable pharmacokinetics
- Do not engage FcγR
- Large-scale production and formation in a cost-effective manner
Creative Biolabs is devoted to assisting sdAb development projects in a high-quality and efficient manner. In terms of our well-established MUsdAb™ platform and seasoned scientists, we are confident in tailoring the best solutions to develop multivalent sdAb for your projects. If you are interested in learning more details, please feel free to contact us.
Reference
- Iezzi, M.; et al. Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment. Frontiers in immunology. 2018, 9: 273.
Case Study
All services are provided for research purposes only. Our services cannot be used for clinical or therapeutic applications.
Services
